Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
Author:
Funder
Seoul National University College of Medicine Research Fund
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Link
http://link.springer.com/content/pdf/10.1186/s12885-018-5211-y.pdf
Reference30 articles.
1. Are C, Ahmad H, Ravipati A, Croo D, Clarey D, Smith L, Price RR, Butte JM, Gupta S, Chaturvedi A, et al. Global epidemiological trends and variations in the burden of gallbladder cancer. J Surg Oncol. 2017;115(5):580–90.
2. Sheth S, Bedford A, Chopra S. Primary gallbladder cancer: recognition of risk factors and the role of prophylactic cholecystectomy. Am J Gastroenterol. 2000;95(6):1402–10.
3. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014;6:99–109.
4. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.
5. Hirooka Y, Ishikawa T, Kawashima H, Ohno E, Nonogaki K, Kanamori A, Hirai T, Uchida H, Shirai O, Ishikawa H, et al. Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer. Cancer Chemother Pharmacol. 2017;80(1):119–25.
Cited by 22 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Prognostic Factors in Patients Diagnosed with Gallbladder Cancer over a Period of 20 Years: A Cohort Study;Cancers;2024-08-23
2. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study;The Lancet Gastroenterology & Hepatology;2024-08
3. Outcomes of Self-expandable Metal Stents in Patients With Unresectable Gallbladder Cancer Undergoing Percutaneous Biliary Drainage;Journal of Clinical and Experimental Hepatology;2024-05
4. Haematologic biomarkers and survival in gallbladder cancer: a systematic review and meta-analysis;ecancermedicalscience;2024-01-30
5. A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer;Cancer Research and Treatment;2023-10-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3